Quality indicators in the treatment of acute ischemic stroke

Abstract

Cerebrovascular diseases are a global medical and social issue because of the high morbidity, mortality and disability they cause. WHO announces 15 Mio ischemic stroke occurrences per year globally, with 5 Mio associated deaths and 5 Mio left permanently disabled. Thrombolysis (TL) with tissue plasminogen activator (rt-PA) is currently an approved differentiated pharmaco-therapeutic treatment of ischemic stroke (IS) in its acute phase. There is irrefutable evidence of better health results and efficient clinical management of ischemic strokes within an integrated therapeutic approach as a key factor for improving the functional outcome in stroke patients. Quality is one of the most widely discussed issues in the theory and practice of disease management. The rigid compliance with the standards for treatment of ischemic strokes is an indicator of high quality patient management.

Stability and Reactivity of Two Benzimidazole Hydrazide-Hydrazone Compounds: A Theoretical Study by DFT Method

“…Nitrogen heterocycles stand out as crucial components in pharmaceutical products owing to the wide array of their biological activities [1][2][3]. In endeavors to enhance these activities, synthetic chemists have integrated benzimidazoles [4][5][6] and Hydrazides-hydrazones [7][8][9] to design new derivatives known as benzimidazoles-hydrazides-hydrazones [10][11][12][13][14]. These compounds have demonstrated activities such as anticancer [12], antibacterial [13] and various other properties [14].…”